Clinical trial
Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily…
NCT00042575 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00042575 |
|---|---|
| Title | Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression |
| Official title | Protocol F1J-US-HMBY Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Major Depressive Disorder |
| Intervention type | Drug |
| Interventions | Duloxetine |
| Enrollment | 120 |
| Start date | Jun 1, 2002 |
| Completion | Aug 1, 2002 |
| First posted | Aug 5, 2002 |
| Last update posted | Jul 19, 2006 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: